Comparing the Effects of Human and Fetal Bovine Serum on Mesenchymal Stem Cells Under Oxidative Stress

Document Type : Original Articles


1 Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Department of Clinical Biochemistry, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.


Objectives: Stem cells are undifferentiated cells capable of creating different types of cell in the body. Stem cell proliferation often is performed in the culture medium supplemented with Fetal Bovine Serum (FBS). Unknown compounds in the FBS, risk of contamination and disease transmission encourages the researches toward finding an alternative to FBS. Several factors are involved in the Mesenchymal Stem Cells (MSCs) precocious death in the transplanted tissue environment. Oxidative Stress (OS) is one of the main causes of stem cell apoptosis in the initial days after transplantation. The aim of this study was to evaluate the effect of Human Serum (HS) on the viability and oxidative related enzymes in human Adipose tissue-Derived Stem Cells (ADSCs) under oxidative stress in comparison with FBS.Materials & Methods: Human serum were obtained from blood of a healthy donor persons, in respective intervals during few days. The ADSCs were isolated from lipolysis operation samples and their cuture media were supplemented with FBS or HS and different concentrations of H2O2 as the oxidative agent.Results: The results showed that cell proliferation and viability of ADSCs under oxidative stress condition was significantly higher in the culture medium supplemented with HS in comparison with FBS supplemented medium (P<0.05).Conclusion: This study showed that FBS could be replaced by HS in MSC culture medium with improved effects on cell proliferation and oxidative related enzyme activity under oxidative Stress condition. 


  1. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy. Journal of Cellular and Molecular Medicine. 2004; 8(3):301–16. doi: 10.1111/j.1582-4934.2004.tb00320.x
  2. Razban V, Lotfi AS, Soleimani M, Ahmadi H, Massumi M, Khajeh S, et al. HIF-1α overexpression induces angiogenesis in mesenchymal stem cells. BioResearch Open Access. 2012; 1(4):174–83. doi: 10.1089/biores.2012.9905
  3. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplantation. 2016; 25(5):829–48. doi: 10.3727/096368915x689622
  4. Razban V, Khajeh S, Lotfi AS, Mohsenifar A, Soleimani M, Khoshdel A, et al. Engineered heparan sulfate-collagen IV surfaces improve human mesenchymal stem cells differentiation to functional hepatocyte-like cells. Journal of Biomaterials and Tissue Engineering. 2014; 4(10):811–22. doi: 10.1166/jbt.2014.1234
  5. Sahebghadam Lotfi A. High yield generation of hepatocyte like cells from adipose derived stem cells. Scientific Research and Essays. 2012; 7(10):1141-7. doi: 10.5897/sre11.1437
  6. Keating A. Mesenchymal stromal cells. Current Opinion in Hematology. 2006; 13(6):419–25. doi: 10.1097/01.moh.0000245697.54887.6f
  7. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F., Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315–7. doi: 10.1080/14653240600855905
  8. Khairoun M, S Korevaar S. Human bone marrow- and adipose tissue-derived mesenchymal stromal cells are immunosuppressive in vitro and in a humanized allograft rejection model. Journal of Stem Cell Research & Therapy. 2013; doi: 10.4172/2157-7633.s6-001
  9. Denu RA, Hematti P. Effects of oxidative stress on mesenchymal stem cell biology. Oxidative Medicine and Cellular Longevity. 2016; 2016:1–9. doi: 10.1155/2016/2989076
  10. Gstraunthaler G. Alternatives to the use of fetal bovine serum: Serum-free cell culture. Altex. 2003; 20(4):275-81. PMID: 14671707
  11. Fernandes-Platzgummer A, Carmelo JG, da Silva CL, Cabral JMS. Clinical-grade manufacturing of therapeutic human mesenchymal stem/stromal cells in microcarrier-based culture systems. Methods in Molecular Biology. 2016; 375–88. doi: 10.1007/978-1-4939-3584-0_22
  12. Bieback K, Hecker A, Kocaömer A, Lannert H, Schallmoser K, Strunk D, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009; 27(9):2331–41. doi: 10.1002/stem.139
  13. Brunner D, Frank J, Appl H, Schöffl H, Pfaller W, Gstraunthaler G. Serum-free cell culture: The serum-free media interactive online database. Altex. 2010; 27(1):53-62. PMID: 20390239
  14. Van der Valk J, Brunner D, De Smet K, Fex Svenningsen Å, Honegger P, Knudsen LE, et al. Optimization of chemically defined cell culture media – Replacing fetal bovine serum in mammalian in vitro methods. Toxicology in Vitro. 2010; 24(4):1053–63. doi: 10.1016/j.tiv.2010.03.016
  15. Taupin P. Derivation of embryonic stem cells for cellular therapy: Challenges and new strategies. Medical Science Monitor. 2006; 12(4):75-8.
  16. Kobayashi T. Motility and growth of human bone-marrow mesenchymal stem cells during ex vivo expansion in autologous serum. Journal of Bone and Joint Surgery - British Volume. 2005; 87(10):1426–33. doi: 10.1302/0301-620x.87b10.16160
  17. Wang Z, Zhang F, Wang L, Yao Y, Zhao Q, Gao X. Lipopolysaccharides can protect mesenchymal stem cells (MSCs) from oxidative stress-induced apoptosis and enhance proliferation of MSCs via toll-like receptor (TLR)-4 and PI3K/Akt. Cell Biology International. 2009; 33(6):665–74. doi: 10.1016/j.cellbi.2009.03.006
  18. Wang X, Zhao T, Huang W, Wang T, Qian J, Xu M, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells. 2009; 27(12):3021-31. doi: 10.1002/stem.230.
  19. Findeisen HM, Pearson KJ, Gizard F, Zhao Y, Qing H, Jones KL, et al. Oxidative stress accumulates in adipose tissue during aging and inhibits adipogenesis. PLoS ONE. 2011; 6(4):18532. doi: 10.1371/journal.pone.0018532
  20. Altaner C, Altanerova V, Cihova M, Ondicova K, Rychly B, Baciak L, et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. International Journal of Cancer. 2013; 134(6):1458–65. doi: 10.1002/ijc.28455
  21. Cucchiarini M, Venkatesan JK, Ekici M, Schmitt G, Madry H. Human mesenchymal stem cells overexpressing therapeutic genes: From basic science to clinical applications for articular cartilage repair. Bio-Medical Materials and Engineering. 2012; 22(4):197-208.
  22. Keyßer G, Müller L, Schendel M, Schmoll H-J. [Therapeutic use of mesenchymal stromal cells in autoimmune diseases (German)]. Zeitschrift für Rheumatologie. 2009; 68(3):220–7. doi: 10.1007/s00393-008-0394-2
  23. Seo JH, Cho S-R. Neurorestoration induced by mesenchymal stem cells: Potential therapeutic mechanisms for clinical trials. Yonsei Medical Journal. 2012; 53(6):1059. doi: 10.3349/ymj.2012.53.6.1059
  24. Valle-Prieto A, Conget PA. Human mesenchymal stem cells efficiently manage oxidative stress. Stem Cells and Development. 2010; 19(12):1885–93. doi: 10.1089/scd.2010.0093